These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 47263)

  • 1. Coagulative and fibrinolytic properties of ascitic fluid associated with ovarian tumors.
    Svanberg L; Astedt B
    Cancer; 1975 May; 35(5):1382-7. PubMed ID: 47263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Paternoster A; Pengo V; Marchesoni D
    Clin Exp Obstet Gynecol; 1981; 8(2):64-5. PubMed ID: 7199979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
    Lu XG; Mao JS; Tong JF; Zhu L; Liu J; Gong XB; Huang J
    Int J Lab Hematol; 2007 Apr; 29(2):132-8. PubMed ID: 17474886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of fibrinolytic activators from human ovarian tumours in organ culture.
    Svanberg L; Astedt B
    Ann Chir Gynaecol; 1976; 65(6):405-7. PubMed ID: 1020906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
    Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
    Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
    Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
    J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
    Wahlberg K; Høyer-Hansen G; Casslén B
    Cancer Res; 1998 Aug; 58(15):3294-8. PubMed ID: 9699658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites.
    Toschi V; Rocchini GM; Motta A; Fiorini GF; Cimminiello C; Violi F; Castelli C; Sironi D; Gibelli A
    Biomed Pharmacother; 1993; 47(8):345-52. PubMed ID: 8061256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation factors in human lymph and plasma.
    Stutman LJ; Dumont AE; Shinowara GY
    Am J Med Sci; 1965 Sep; 250(3):292-7. PubMed ID: 5829382
    [No Abstract]   [Full Text] [Related]  

  • 10. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulant, fibrinolytic, and aggregating activity in ascitic fluid.
    Baele G; Rasquin K; Barbier F
    Am J Gastroenterol; 1986 Jun; 81(6):440-3. PubMed ID: 3706262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clotting and fibrinolytic activities in peritoneal fluid.
    Pattinson HA; Koninckx PR; Brosens IA; Vermylen J
    Br J Obstet Gynaecol; 1981 Feb; 88(2):160-6. PubMed ID: 6779852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems.
    Gilabert-Estellés J; Ramón LA; España F; Gilabert J; Vila V; Réganon E; Castelló R; Chirivella M; Estellés A
    Hum Reprod; 2007 Aug; 22(8):2120-7. PubMed ID: 17609243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
    Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
    Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumours.
    Zhu GG; Melkko J; Risteli J; Kauppila A; Risteli L
    Clin Chim Acta; 1994 Sep; 229(1-2):87-97. PubMed ID: 7988058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin is detectable in the ascitic fluid in patients with ovarian tumors.
    Stefanovic V; Pakarinen P; Alfthan H; Stenman UH; Leminen A; Pociuviene J; Riska A; Loukovaara M
    Int J Gynecol Cancer; 2012 Nov; 22(9):1470-3. PubMed ID: 23027039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of activation of rabbit plasminogen by urokinase. Lack of a preactivation peptide.
    Sodetz JM; Brockway WJ; Mann KG; Castellino FJ
    Biochem Biophys Res Commun; 1974 Sep; 60(2):729-36. PubMed ID: 4278813
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system.
    LeBlanc PP; Back N
    J Natl Cancer Inst; 1975 Apr; 54(4):881-6. PubMed ID: 123966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
    Zacharski LR; Memoli VA; Ornstein DL; Rousseau SM; Kisiel W; Kudryk BJ
    J Natl Cancer Inst; 1993 Aug; 85(15):1225-30. PubMed ID: 8331683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies.
    Varcaccio-Garofalo G; Selvaggi L; Capozza G; Orlando E; Ferreri R; Restaino A
    Eur J Gynaecol Oncol; 1982; 3(2):113-4. PubMed ID: 7166171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.